Immunome(IMNM) - 2024 Q1 - Quarterly Results

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update BOTHELL, Wash. – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in- class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. Exhibit 99.1 "Immunome continues to build momentum. We have completed the integration of AL102 and are executing activities necessary for regulatory submissions," s ...